EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Shares of Trump Media & Technology Group (DJT 3.17%) are falling this week. The company's stock had plummeted 16.7% at 2:16 p.m. ET. The fall comes as the S&P 500 index has risen 1.4% and the Nasdaq-100 index has risen 1.1%.Trump Media announced on Tuesday that it is pursuing a new strategy of Bitcoin accumulation. The company is raising $2.5 billion in a private deal to create what will be the largest Bitcoin reserve held by a private company.Strategy's strategyFollowing in the footsteps of Michael Saylor' ...

SAN FRANCISCO, May 30, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025. The lawsuit comes after investors saw the price of their shares in UroGen Pharma Ltd. (NASDAQ: URGN) crash on May 16, 2025 as a result of the FDA’s publication of a briefing document a few days before an upcoming O ...

Shares of Abercrombie & Fitch (ANF -3.14%) are trading higher this week. The company's stock jumped 9.7% as of 2:15 p.m. ET. The move up comes as the S&P 500 (^GSPC -0.25%) and the Nasdaq-100 were up 1.4% and 1.1%, respectively.The clothing retailer released its quarterly numbers on Wednesday, beating Wall Street targets at a time when other retailers are struggling.Abercrombie is growingAbercrombie posted a strong quarter and set relatively optimistic guidance, even in the face of uncertainty around Trump' ...

Shares of Summit Therapeutics (SMMT -28.35%) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning.Summit has been a tremendous winner over the past year, as its bispecific antibody lung cancer drug ivonescimab outperformed prior standards of care in phase 3 trials performed in China by Summit's partner Akeso (AKES.F -4.96%).While today's results weren't all bad by any means, apparently investors had hoped for more conclusive information about survival rates. With ...

NEW YORK, May 30, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GoHealth, Inc. (NASDAQ: GOCO) resulting from allegations that GoHealth may have issued materially misleading business information to the investing public.So What: If you purchased GoHealth securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen ...

I publish my best ideas and top coverage in the Growth Stock Forum . We focus on attractive risk/reward situations and track each of our portfolio stocks, Top Picks and Trading Ideas closely. If you're interested in finding great growth stocks, consider signing up to Growth Stock Forum. Join by June 9, to lock in the current rates before prices increase.Shares of Sanofi (NASDAQ: SNY ) and its partner Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) are down today after the companies announced that itepekimab ...

Subscribers to Schaeffer's Weekend Trader options recommendation service received this BWXT commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters. Learn more about why Weekend Trader is one of our most popular options trading services.Shares of BWX Technologies Inc (NYSE:BWXT) are enjoying support at their March and July 2024 highs as they break above resistance at the $110-$111 range. What’s more, all daily moving averages are moving ...

BioLineRx Ltd’s BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.The CheMo4METPANC trial is evaluating motixafortide, cemiplimab, and standard-of-care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).Updated results from the pilot phase indicat ...

Core Viewpoint - The Gap, Inc. reported strong first-quarter fiscal 2024 results, with both earnings and net sales exceeding expectations and showing year-over-year growth [1][3]. Financial Performance - Earnings per share were 51 cents, surpassing the Zacks Consensus Estimate of 44 cents, and increased by 24% from the previous year [3]. - Net sales rose by 2% year over year to $3.46 billion, exceeding the consensus estimate of $3.42 billion [3]. - Comparable sales also increased by 2% year over year, with online sales growing by 6% and accounting for 39% of total sales [3]. Brand Performance - Old Navy's net sales increased by 3% year over year to $2 billion, marking its ninth consecutive quarter of market share gains [5]. - Gap Global saw a 5% year-over-year increase in net sales to $724 million, achieving its sixth straight quarter of positive comps [6]. - Banana Republic's net sales decreased by 3% year over year to $428 million, while Athleta's net sales dropped by 6% to $308 million [7]. Margins and Costs - The gross margin improved to 41.8%, up 60 basis points year over year [8]. - The operating margin increased to 7.5%, growing by 140 basis points from the previous year [9]. - Operating expenses were reported at $1.2 billion, a slight decrease of 0.3% year over year [10]. Financial Health - Cash and cash equivalents at the end of the quarter were $1.98 billion, a 29.4% increase from the previous year [11]. - Total stockholders' equity stood at $3.3 billion, with long-term debt of $1.5 billion [11]. - Merchandise inventory rose by 7.7% year over year to $2.1 million [11]. Future Outlook - For fiscal 2025, the company projects sales growth of 1-2% from $15.1 billion in fiscal 2024, driven by Old Navy and Gap's performance [15]. - Management anticipates a slight increase in gross margin and expects to achieve approximately $150 million in cost savings [16]. - Operating income is projected to rise by 8-10% from the previous year's figure of $1.11 billion, excluding tariff impacts [17].